Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Conditions:   Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content;   Head and Neck Cancer;   Non-small Cell Lung Cancer;   Gastric Cancer;   Esophageal Cancer;   Pancreas Cancer;   Bladder Cancer;   Renal Cell Carcinoma;   Melanoma;   Triple-negative Breast Cancer;   Ovarian Cancer
Intervention:   Drug: ADCT-301
Sponsor:   ADC Therapeutics S.A.
Not yet recruiting

https://ift.tt/2vyL5Ds